Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title | FOA | Organization | Release Date | Expire Date | Purpose |
|---|---|---|---|---|---|
| NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required) | PAR-24-083 | NCCIH | This notice of funding opportunity (NOFO) invites applications for investigator-initiated clinical trials of complementary and integrative health approaches with physical and/or psychological… More | ||
| Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional) | PAR-21-206 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to stimulate efforts to translate scientific discoveries and engineering developments into methods or tools that address problems in… More | ||
| Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional) | PAR-21-334 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium… More | ||
| Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed) | PAR-21-335 | NCI | The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Research Units (RUs), one of the two scientific components of the Pancreatic Cancer Detection Consortium… More | ||
| Cancer Immunoprevention Network (CIP-Net) ?Research Projects (UG3/UH3 Clinical Trials Not Allowed) | RFA-CA-23-029 | NCI | The purpose of the Cancer Immunoprevention Network (CIP-Net) is to support a deeper understanding of basic mechanisms of immunoprevention, discover novel immunoprevention strategies, and foster a… More | ||
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional) | RFA-CA-24-022 | NCI | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek… More | ||
| Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Allowed) | RFA-CA-24-023 | NCI | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support early-career academic scientists interested in transitioning to entrepreneurship while also… More | ||
| Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional) | PAR-21-331 | NCI | Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated studies addressing mechanisms by which bariatric… More | ||
| NCI Transition Career Development Award to Promote Diversity (K22 Independent Clinical Trial Not Allowed) | PAR-21-301 | NCI | The purpose of the NCI Transition Career Development Award to Promote Diversity (K22) is to assist postdoctoral fellows or individuals in equivalent positions to transition to positions of assistant… More | ||
| Basic Research in Cancer Health Disparities (R03 Clinical Trial Not Allowed) | PAR-21-324 | NCI | This Funding Opportunity Announcement (FOA) encourages grant applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health… More |